283 related articles for article (PubMed ID: 14555310)
21. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
24. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
26. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
27. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
Lim SH; Bailey-Wood R
Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
[TBL] [Abstract][Full Text] [Related]
28. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
[TBL] [Abstract][Full Text] [Related]
29. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
30. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
Zahradova L; Mollova K; Ocadlikova D; Kovarova L; Adam Z; Krejci M; Pour L; Krivanova A; Sandecka V; Hajek R
Neoplasma; 2012; 59(4):440-9. PubMed ID: 22489700
[TBL] [Abstract][Full Text] [Related]
32. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
33. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
[TBL] [Abstract][Full Text] [Related]
34. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
Chang GC; Lan HC; Juang SH; Wu YC; Lee HC; Hung YM; Yang HY; Whang-Peng J; Liu KJ
Cancer; 2005 Feb; 103(4):763-71. PubMed ID: 15637694
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
36. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry.
Maecker HT; Auffermann-Gretzinger S; Nomura LE; Liso A; Czerwinski DK; Levy R
Clin Cancer Res; 2001 Mar; 7(3 Suppl):902s-908s. PubMed ID: 11300490
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination.
Pedersen AE; Thorn M; Gad M; Walter MR; Johnsen HE; Gaarsdal E; Nikolajsen K; Buus S; Claesson MH; Svane IM
Scand J Immunol; 2005 Feb; 61(2):147-56. PubMed ID: 15683451
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
39. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
40. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
Kim SB; Baskar S; Kwak LW
Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
